Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
Loading...
Embargo End Date
ICR Authors
Authors
Mateo, J
de Bono, JS
Fizazi, K
Saad, F
Shore, N
Sandhu, S
Chi, KN
Agarwal, N
Olmos, D
Thiery-Vuillemin, A
Özgüroğlu, M
Mehra, N
Matsubara, N
Young Joung, J
Padua, C
Korbenfeld, E
Kang, J
Marshall, H
Lai, Z
Barnicle, A
Poehlein, C
Lukashchuk, N
Hussain, M
de Bono, JS
Fizazi, K
Saad, F
Shore, N
Sandhu, S
Chi, KN
Agarwal, N
Olmos, D
Thiery-Vuillemin, A
Özgüroğlu, M
Mehra, N
Matsubara, N
Young Joung, J
Padua, C
Korbenfeld, E
Kang, J
Marshall, H
Lai, Z
Barnicle, A
Poehlein, C
Lukashchuk, N
Hussain, M
Document Type
Journal Article
Date
2024-02-10
Date Accepted
2023-08-16
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Citation
Journal of Clinical Oncology, 2023, pp. JCO2300339 -
Source Title
Journal of Clinical Oncology
Publisher
LIPPINCOTT WILLIAMS & WILKINS
ISSN
0732-183X
eISSN
1527-7755
1527-7755
1527-7755
Collections
Research Team
PrCa Targeted Therapy